CEL-SCI Presents Head & Neck Cancer Data At IDDST Annual Congress In Budapest: Risk Of Death Cut In Half For Patients Treated With Multikine In The Target Population
Portfolio Pulse from Benzinga Newsdesk
CEL-SCI Corporation presented promising data at the IDDST Annual Congress showing that their Multikine treatment significantly improves survival rates for head and neck cancer patients with low PD-L1 expression. The treatment cut the 5-year risk of death in half and showed a 73% survival rate compared to 45% in the control group. CEL-SCI is working towards an FDA confirmatory registration study for Multikine.
June 18, 2024 | 12:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CEL-SCI's Multikine treatment has shown significant improvement in survival rates for head and neck cancer patients, cutting the 5-year risk of death in half. The company is preparing for an FDA confirmatory registration study.
The significant improvement in survival rates and the preparation for an FDA confirmatory study are likely to positively impact CEL-SCI's stock price in the short term. Investors may view this as a strong indicator of future success and potential market approval.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100